Bankers and buysiders are not expecting a repeat performance of biotech's stellar 2013. But the two dozen who spoke with BioCentury say the capital markets are primed to open back up this month, albeit on a more selective and price-sensitive basis.

The sector experienced a modest slowdown during the latter portion of 2013 due to a combination of profit-taking, deal fatigue and several high-profile setbacks that offered generalist investors a useful reminder of biotech's inherent riskiness.